A double-blind, randomised, placebo-controlled study in 215 elderly nursing home
residents showed that Lactobacillus reuteri Prodentis reduced the prevalence of
oral Candida by more than 50 per cent compared to placebo.
“The results show that Lactobacillus reuteri Prodentis may be beneficial in
patients at risk of oral candidosis”, says Professor Svante Twetman, Department
of Odontology, Faculty of Health and Medical Sciences, University of Copenhagen,
Denmark.
After 12 weeks of intervention with two lozenges per day of Lactobacillus
reuteri Prodentis there was a statistically significant reduction of 53 per cent
in the proportion of patients that had high Candida counts in both saliva and
plaque in the probiotic group whereas there was no difference in the placebo
group.
Candida a common problem
Oral candidosis, or Candida-associated stomatitis, is common among the elderly
and is often associated with factors such as antibiotic treatment, an impaired
immune system, neglected oral hygiene and smoking.
In frail elderly patients the condition may be more or less chronic or
frequently recurrent and may require long-term or repeated antifungal medication
with the risk of resistant strains. Furthermore, the long-term effects of
antifungal drugs on the oral microbiota are unclear.
”As Candida affects a large number of our elderly population the new and
positive results could make BioGaia’s oral health probiotic ProDentis an
attractive alternative to conventional antifungal drugs”, says Peter Rothschild,
President, BioGaia.
The study was published in Journal of Dental
Research (http://jdr.sagepub.com/content/early/2015/07/22/0022034515595950.abstr
a
ct) 22 July 2015. Study facts are found
here (http://www.biogaia.com/sites/biogaia.com/files/Study_facts_Twetman_2015.pd
f
).
Latest press releases from BioGaia
2015-06-30 Number of shares in BioGaia
2015-06-24 BioGaia subsidiary IBT takes rapid steps in development of a drug for
premature infants
2015-06-12 BioGaia evaluates the possibility of a separate listing of Infant
Bacterial Therapeutics AB
BioGaia has published this information in accordance with the Swedish Securities
Market Act. The information was issued for publication on 30 July 2015, 01:00 pm
CET.
For additional information please contact
Peter Rothschild, Chief Executive Officer, BioGaia: 46 8 555 293 00
BioGaia is a healthcare company that develops, markets and sells probiotic
products with documented health benefits. The products are primarily based on
the lactic acid bacterium Lactobacillus reuteri, which has probiotic, health
-enhancing effects. The class B share of the Parent Company BioGaia AB is quoted
on the Mid Cap list of the NASDAQ OMX Nordic Exchange Stockholm. www.biogaia.com
